COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
Zomedica Corp. reports consolidated financial results for Q4 and full year 2023, showing significant revenue growth and progress. CEO Larry Heaton highlights momentum and strategic acquisitions for future growth -
-
-
COMMUNIQUÉ DE PRESSE
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
Zomedica Corp. (NYSE American: ZOM) to host conference call on April 1, 2024, discussing operational and financial highlights for Q4 and full year 2023. Company specializes in veterinary health products for companion animals -
-
-
COMMUNIQUÉ DE PRESSE
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
Zomedica Corp. announced the publication of a peer-reviewed research study comparing its TRUFORMA BAW diagnostic platform to CLIA platforms for feline hyperthyroidism diagnosis, showing superior accuracy and potential for early detection
